Meryx, Inc. clinical trials

Acquired by Betta Pharmaceuticals Co., Ltd., 2021 · source ↗

The registry lists 2 studies whose lead sponsor is Meryx, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 8, 2026.

Before and after it joined Betta Pharmaceuticals Co., Ltd.

First submitted before Meryx, Inc. became part of Betta Pharmaceuticals Co., Ltd.: 1
First submitted after Meryx, Inc. became part of Betta Pharmaceuticals Co., Ltd.: 0
Unclear, or no submission date: 1

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Recruiting: 1
Completed: 1

Phase

Phase 1: 2

Where

United States: 2

Registry sponsor names on this page

Meryx, Inc.2 studies

Something wrong with this grouping? Tell us on the Betta Pharmaceuticals Co., Ltd. page.

Studies

Recruiting first, then most recently updated. Showing 2 of 2. All Betta Pharmaceuticals Co., Ltd. studies →

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPALRecruitingNCT04872478Phase 1
Sponsor listed in the registry: Meryx, Inc. · Unclear whether first submitted before or after Meryx, Inc. became part of Betta Pharmaceuticals Co., Ltd.
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid TumorsCompletedNCT03510104Phase 1
Sponsor listed in the registry: Meryx, Inc. · First submitted before Meryx, Inc. became part of Betta Pharmaceuticals Co., Ltd.